Ukko

UkkoUkko
Ukko

Ukko

Ukko is developing novel food allergy and disorder treatments using advanced immunology and plant science.

DR 202016Active58Palo Alto, United States
Rate

About

Ukko is dedicated to improving the lives of individuals suffering from food allergies and disorders. They leverage cutting-edge technologies in immunology, computational biology, and plant science to create innovative therapeutic approaches. The company has a presence in Tel Aviv, Israel, and Palo Alto, California.
Frequently asked

What does Ukko do?

Ukko is dedicated to improving the lives of individuals suffering from food allergies and disorders. They leverage cutting-edge technologies in immunology, computational biology, and plant science to create innovative therapeutic approaches. The company has a presence in Tel Aviv, Israel, and Palo Alto, California.

What is Ukko's revenue?

StartupHub estimates Ukko's annual revenue at $16.9M (range $11.2M to $28.4M, 66% confidence), based on comparable companies in the sector.

What is Ukko's valuation?

StartupHub estimates Ukko's effective valuation at $169.6M (range $100.0M to $240.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Ukko raised?

Ukko has raised a total of $40M in funding. The most recent round on record is Series B.

Where is Ukko headquartered?

Ukko is headquartered in Palo Alto, United States.

When was Ukko founded?

Ukko was founded in 2016.

What industry does Ukko operate in?

Ukko operates in Healthcare, Allergen, Immunology, Celiac, Genomics, HealthTech.

How many employees does Ukko have?

Ukko has approximately 58 people on record.

HEADCOUNT
58
DOMAIN RATING
20
New entrants in Healthcare
Last 90 days
2
New entrants
0.7
Per month
0.2
Per week

An entrant is a company tagged Healthcare whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.

Comments

No comments yet. Be the first to share your take.